Apathy Cure Through Bupropion in Huntington's Disease

Phase 2

Completed

• Conditions: Huntington's Disease; Apathy
• Interventions: Drug: Bupropion; Drug: Placebo

• Registration Number: NCT01914965
• Lead Sponsor: Charite University, Berlin, Germany

Brief Summary

The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I \[informant\] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten (10) weeks of treatment.

Detailed Description

The safety and tolerability of Bupropion in HD.

The influence of Bupropion compared to placebo on the:

* change of apathy as quantified by the AES-C (clinician) or the AES-S (self),

* change of motor symptoms (UHDRS) and quantitative grip force motor assessment,

* change of cognitive symptoms (UHDRS and MMSE),

* change of psychiatric symptoms (UHDRS, HADS),

* change of activities of daily living (UHDRS),

* change of the NPI caregivers' distress score (NPI-D),

* change of ventral striatal and ventromedial prefrontal activation in response to a reward paradigm as quantified by fMRI.

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2013-07-31
• Study First Submitted QC: 2013-07-31
• Study First Posted: 2013-08-02
• Primary Completion: 2014-05
• Study Completion: 2014-05
• Status Verified: 2014-09
• Last Update Submitted: 2014-09-08
• Last Update Posted: 2014-09-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Verified HD mutation carriers aged 25 to 75 years (inclusive) at first dosing
2. Apathetic as diagnosed by SCIA-D criteria
3. Stable concomitant medication (no change of medication during last six weeks prior to inclusion)
4. Written informed consent by prospective study participant before conduct of any trial-related procedure. Participant must be able to make an informed decision of whether or not to participate in the study
5. Patient has a caregiver (family member or friend), who is living in a close relationship with the patient and is willing to give written informed consent (caregiver) before performance of any trial-related procedure

Exclusion criteria:

1. Pregnant or nursing women
2. Active suicidality based on the answer "yes" in questions 4 and 5 of the Columbia-Suicide Severity Rating Scale (baseline version)
3. Woman of childbearing potential, not using highly effective methods of contraception defined as methods with a Pearl Index < 1 such as oral, topical or injected contraception, IUD, contraceptive vaginal ring, or double barrier method such as diaphragm and condom with spermicide) or not surgically sterile (via hysterectomy, ovariectomy or bilateral tubal ligation) or not at least one year post-menopausal
4. Male not using an acceptable barrier method for contraception and donating sperm from screening up to three months following treatment
5. Presence or history of any medically not controllable disease (e.g. uncontrolled arterial hypertension or diabetes mellitus)
6. Presence or history of seizures or diagnosed epilepsy or history of severe head trauma (contusion) or CNS tumor
7. Clinical significant renal (calculated creatine clearance < 60 ml/min) or hepatic dysfunction
8. Clinical significant depression defined by the NPI depression score (score ≥4 points) at screening
9. Schizophreniform psychosis within the last 6 months prior to first dose
10. History of anorexia or bulimia
11. Severe cognitive disorders defined as a score < 18 in the Mini- Mental State Examination (MMSE) at screening
12. Marked chorea (UHDRS 4) of face, BOL, trunk or extremities
13. Treatment with neuroleptics other than tiapride, MAO-B inhibitors, amantadine, levodopa, D- or D,L-amphetamine or psychostimulants like methylphenidate, modafinil or atomoxetine within 1 month prior to first dose
14. Known hypersensitivity reaction associated with bupropion, gelatine, lactose or magnesium stearate
15. Clinically relevant abnormal findings in the ECG, the vitals, in the physical examination or laboratory values at screening that could interfere with the objectives of the study or the safety of the subject as judged by the investigator
16. Acute disease state (e.g. nausea, vomiting, fever, diarrhoea, infection) within 7 days of first dose
17. Definite or suspected personal history or family history of adverse reactions or hypersensitivity to the trial compounds (or to compounds with a similar structure)
18. Presence of illicit drug and/or alcohol abuse
19. Participation in another investigative drug trial within 2 months or donation of blood within 12 weeks prior to the first dose or during the trial
20. Subjects who are unlikely to be compliant and attend scheduled clinic visits as required
21. Placement in an institution due to governmental or judicial authorities

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Bupropion	Placebo	First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
Placebo	Placebo	Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
Bupropion	Bupropion	First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
Placebo	Bupropion	Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days

Primary Outcome Measures

Name	Time	Method
Apathy Evaluation Scale (AES-I)	10 weeks	The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I \[informant\] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
Psychiatric symptoms	10 weeks	The influence of Bupropion compared to placebo on UHDRS behavioural assessment in patients with HD after ten weeks of treatment.
Caregiver's distress	10 weeks	The influence of Bupropion compared to placebo on the NPI caregiver's distress score.
Adverse events	10 weeks	The safety and tolerability of Bupropion will be compared with placebo in patients with HD after ten weeks of treatment.
AES-C (clinician)	10 weeks	The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-C, where C \[clinician\] is the trial investigator) in patients with HD after ten weeks of treatment.
AES-S (self)	10 weeks	The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-S, where S \[self\] is the patient) in patients with HD after ten weeks of treatment.
Quantitative grip force motor assessment	10 weeks	The influence of Bupropion compared to placebo on motor scores in patients with HD after ten weeks of treatment.
Cognitive Symptoms	10 weeks	The influence of Bupropion compared to placebo on MMSE in patients with HD after ten weeks of treatment.
ventral striatal and ventromedial prefrontal activation	10 weeks	Change of ventral striatal and ventromedial prefrontal activation in response to a reward paradigm as quantified by fMRI.
Activities of daily living	10 weeks	The influence of Bupropion compared to placebo on UHDRS Functional Assessment in patients with HD after ten weeks of treatment.
Motor symptoms (UHDRS)	10 weeks	The influence of Bupropion compared to placebo on the UHDRS motor score in patients with HD after ten weeks of treatment.

Trial Locations

Locations (2)

Neurologische Klinik der Ruhr-Universität Bochum; 🇩🇪 Bochum, Germany

Universitätsklinikum Ulm, Klinik für Neurologie; 🇩🇪 Ulm, Germany